AtriCure vs iRhythm
ATRC and IRTC side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRC and IRTC compare
AtriCure and iRhythm are about the same size, with market caps of $2.8B and $3.0B.
iRhythm grew revenue faster over the last twelve months (25.6% versus 13.9% for AtriCure).
AtriCure keeps more of each dollar of sales as profit, with a net margin of 1.9% compared with −1.7% at iRhythm.
AtriCure scores higher on the StockData Score (12 against 9 for iRhythm), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRC | IRTC |
|---|---|---|
| Size and price | ||
| Market cap | $2.8B | $3.0B |
| Share price | $55.02 | $89.67 |
| Change, 1 year | 67.2% | −47.5% |
| Change, 5 years | −22.5% | −8.5% |
| Beta (5Y) | 0.47 | 1.39 |
| Employees | 1,350 | 2,400 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 | 4 |
| Performance score | 3 | 3 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 262× | – |
| P/S | 4.9× | 3.6× (better) |
| P/B | 5.4× (better) | 15.9× |
| EV/EBITDA | 209× | – |
| P/FCF | 52.7× (better) | 75.8× |
| FCF yield | 1.9% (better) | 1.3% |
| Fair value | $5.54 | $92.19 |
| Margin of safety | −893% | 2.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.9% | 25.6% (better) |
| Revenue growth, 5Y average | 20.9% | 23.0% (better) |
| Profitability | ||
| Gross margin | 76.3% (better) | 71.5% |
| Operating margin | 2.3% (better) | −3.0% |
| Net margin | 1.9% (better) | −1.7% |
| FCF margin | 9.3% (better) | 4.7% |
| Return on equity | 2.2% (better) | −9.6% |
| Return on invested capital | 2.7% | – |
| Financial health | ||
| Debt / equity | 0.12 | – |
| Net debt / EBITDA | −8.28 | – |
| Interest coverage | 2.3× (better) | −1.9× |
| Current ratio | 4.22 (better) | 3.85 |
| Altman Z-score | 11.02 (better) | 2.20 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 108% |
| Held by insiders | 4.0% | 2.1% |
| Insider net buying, 12 months | −$4.4M (better) | −$24.4M |
| Short interest, % of float | 10.0% | 10.1% |
Go deeper
- ATRC stock overview
- ATRC income statement
- ATRC valuation and score
- IRTC stock overview
- IRTC income statement
- IRTC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.